Nichi-Iko Moots Digital Joint Venture
May Build On Collaboration With MedPeer Digital Services Provider
Nichi-Iko is exploring the possibility of a joint venture with digital services provider MedPeer, building on a collaboration that the Japanese generics firm believes will represent a “new generic drugs business model.”
You may also be interested in...
Despite seeing sales through its US Sagent unit hit by supply issues with CMOs, Nichi-Iko says its US profits have increased on the back of newly-launched products. However, this failed to offset the impact of NHI price revisions in Japan, dragging down profits in the first nine months of the year.
Nichi-Iko and Eisai have announced plans to build on their Japanese generics collaboration by expanding the partnership into China.
Regulators in North America and Europe are reacting to the discovery of the impurity NMDA in ranitidine, just over a year after similar impurities in sartan products led to a slew of recalls and withdrawals around the world.